about
Mycobacterial efflux pumps and chemotherapeutic implications.Leishmaniasis: efflux pumps and chemoresistance.A rat model of diabetic wound infection for the evaluation of topical antimicrobial therapies.Phenothiazines alter resistance of methicillin-resistant strains of Staphylococcus aureus (MRSA) to oxacillin in vitro.Cell mediated immunity and specific IgG1 and IgG2 antibody response in natural and experimental canine leishmaniosis.Inhibition of the Carpobrotus edulis methanol extract on the growth of phagocytosed multidrug-resistant Mycobacterium tuberculosis and methicillin-resistant Staphylococcus aureus.Clinical concentrations of thioridazine enhance the killing of intracellular methicillin-resistant Staphylococcus aureus: an in vivo, ex vivo and electron microscopy study.Carpobrotus edulis methanol extract inhibits the MDR efflux pumps, enhances killing of phagocytosed S. aureus and promotes immune modulation.Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis.Chlorpromazine has intracellular killing activity against phagocytosed Staphylococcus aureus at clinical concentrations.Intracellular activity of clinical concentrations of phenothiazines including thioridiazine against phagocytosed Staphylococcus aureus.Gamma delta T cell responses associated with the development of tuberculosis in health care workers.Cytokine expression during the outcome of canine experimental infection by Leishmania infantum.Direct application of the INNO-LiPA Rif.TB line-probe assay for rapid identification of Mycobacterium tuberculosis complex strains and detection of rifampin resistance in 360 smear-positive respiratory specimens from an area of high incidence of mulInducement and reversal of tetracycline resistance in Escherichia coli K-12 and expression of proton gradient-dependent multidrug efflux pump genes.Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis.EC300: a phage-based, bacteriolysin-like protein with enhanced antibacterial activity against Enterococcus faecalis.A two-component, multimeric endolysin encoded by a single gene.In vitro design of a novel lytic bacteriophage cocktail with therapeutic potential against organisms causing diabetic foot infections.Wound healing potential of topical bacteriophage therapy on diabetic cutaneous wounds.Phage endolysins with broad antimicrobial activity against Enterococcus faecalis clinical strains.Novel Chimerical Endolysins with Broad Antimicrobial Activity Against Methicillin-Resistant Staphylococcus aureus
P50
Q35295692-89E4F85A-664E-4014-92C2-75860DC19986Q35295776-D7CD5718-3B7E-40B7-83EC-C77D101E42A3Q35747517-1E01E384-65CD-4B9F-A55E-8F318A3DA415Q39148696-17CBDB9B-4781-4020-9939-0502D47D3399Q39165078-C0F51DC1-FB69-4066-82E6-71D5947E086DQ39220023-481A7485-7BA8-4F63-ADDD-DC4FDC3F1FBFQ39220028-B2794179-10B7-4D1A-B641-20F3553B2691Q39326455-296B2E1D-CF70-4DA0-8527-3506BE6338E7Q39326462-C8E0EFAE-6910-47FA-AF34-2177EA40E5FCQ39326470-E2B921B3-E001-482A-9358-231DC6865093Q39326476-BCEC0C1D-9F92-4355-ADF5-69B0CCB3D91DQ39326485-B1C23438-BDF7-44EC-B14C-910B2810100BQ39430352-4961A5A3-2181-430B-AC71-BA1087144E51Q39563375-D35A3F53-8D07-46C3-BAAC-E7CB18C26207Q39563388-6E7CEDB5-38F1-4977-AB1F-C1C8E8517097Q39563402-52E02531-3E3D-47E0-A236-E90D3CA592EBQ41457130-11C08E09-CAF6-4F7C-94D5-D0F1257F27BAQ41667348-D64662E2-E706-47A7-A836-E2C04AC11B13Q42216330-C63DA4DC-45E8-4BB7-A37C-8BE717D054FFQ43700519-C5AAD353-DC76-4482-8729-952C1D063537Q45373999-04F917C7-9492-412D-982F-7C956B16798CQ57846750-ECD18CED-F3DA-4EF7-9D9F-5723CDDD4A6B
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Clara Leandro
@ast
Clara Leandro
@en
Clara Leandro
@es
Clara Leandro
@nl
Clara Leandro
@sl
type
label
Clara Leandro
@ast
Clara Leandro
@en
Clara Leandro
@es
Clara Leandro
@nl
Clara Leandro
@sl
prefLabel
Clara Leandro
@ast
Clara Leandro
@en
Clara Leandro
@es
Clara Leandro
@nl
Clara Leandro
@sl
P1053
A-9349-2015
P106
P21
P31
P3829
P496
0000-0002-2382-346X